Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 7, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.

Jovenel Cherenfant1, Susan J Stocker, Mistry K Gage

  • 1NorthShore University HealthSystems, Evanston, IL.

Surgery
|October 1, 2013
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamic Prognostic Nutritional Index With Circulating Tumor DNA Predicts Survival in Localized Pancreatic Ductal Adenocarcinoma.

Journal of surgical oncology·2026
Same author

Hospital Volume and Post-Hepatectomy Liver Failure After Major Hepatectomy.

Journal of surgical oncology·2026
Same author

Contemporary Microhematuria Evaluation in Veterans: Cancer Detection and Resource Utilization.

Urology·2026
Same author

Follow-Up for Node-Negative Patients After Resection for Pancreatic Neuroendocrine Tumor.

JAMA surgery·2025
Same author

MRI Utilization Rates for Veterans at Risk of Prostate Cancer.

JAMA network open·2025
Same author

Reply to: Response to Neoadjuvant Chemotherapy and Breast Cancer Subtypes.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Predicting the behavior of nonfunctioning pancreatic neuroendocrine tumors (PNETs) is challenging. Age over 55, grade 3 histology, and distant metastasis are key indicators of increased mortality risk in PNET patients.

Area of Science:

  • Oncology
  • Surgical Pathology
  • Cancer Research

Background:

  • Nonfunctioning pancreatic neuroendocrine tumors (PNETs) exhibit variable biologic potential, making pre-resection risk stratification difficult.
  • Accurate prediction of malignant behavior and patient outcomes is crucial for effective management strategies.

Purpose of the Study:

  • To identify clinical and pathological factors associated with malignant behavior and mortality in patients with nonfunctioning PNETs.
  • To improve risk stratification and guide treatment decisions for PNETs.

Main Methods:

  • Retrospective analysis of 128 patients who underwent pancreatectomy for PNETs between 1998 and 2011.
  • Multivariate Cox proportional hazard models were used to assess factors related to distant metastasis and survival.

Related Experiment Videos

Last Updated: May 7, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Main Results:

  • Age >55 years (HR, 5.89), grade 3 histology (HR, 6.08), and distant metastasis (HR, 8.79) were significant predictors of death.
  • Tumor size, gender, BMI, and presenting symptoms did not significantly correlate with metastasis or survival.
  • Three patients with tumors ≤2 cm developed distant metastasis, highlighting that size alone is not a reliable indicator of prognosis.

Conclusions:

  • Age >55, grade 3 histology, and distant metastasis are critical risk factors for mortality in nonfunctioning PNETs.
  • Management decisions, including resection or surveillance, should not solely depend on tumor size.